{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["CRF1 receptor antagonist", "Corticotropin-releasing factor level", "Fluoxetine", "Forced swim test", "Imipramine", "Rats"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "28429110", "DateCompleted": {"Year": "2018", "Month": "05", "Day": "09"}, "DateRevised": {"Year": "2018", "Month": "12", "Day": "02"}, "Article": {"ArticleDate": [{"Year": "2017", "Month": "04", "Day": "20"}], "Language": ["eng"], "ELocationID": ["10.1007/s00210-017-1377-0"], "Journal": {"ISSN": "1432-1912", "JournalIssue": {"Volume": "390", "Issue": "8", "PubDate": {"Year": "2017", "Month": "Aug"}}, "Title": "Naunyn-Schmiedeberg's archives of pharmacology", "ISOAbbreviation": "Naunyn Schmiedebergs Arch Pharmacol"}, "ArticleTitle": "Inhibition of the CRF<sub>1</sub> receptor influences the activity of antidepressant drugs in the forced swim test in rats.", "Pagination": {"StartPage": "769", "EndPage": "774", "MedlinePgn": "769-774"}, "Abstract": {"AbstractText": ["Hyperactivity of the hypothalamic-pituitary-adrenal axis (HPA) and impairment of the central corticotropin-releasing factor (CRF) system are factors in the pathogenesis of depression. Though several antagonists of the CRF<sub>1</sub> receptor were effective in the recognized behavioral tests for antidepressant activity, there is still little information on the potential interactions between CRF<sub>1</sub> receptor inhibitors and conventional antidepressant therapy. The aim of our study was to assess the influence of SN003, a CRF<sub>1</sub> receptor blocker, on the activity of imipramine and fluoxetine in the forced swim test (FST) in rats which presented some signs of depression. The experiments were carried out on female Wistar rats subjected to 14-day subcutaneous corticosterone (CORT) administration (20\u00a0mg/kg/day). The antidepressant-like effect was determined by the FST and the CRF levels in the hypothalamus, amygdala, and peripheral blood were measured by a high-sensitivity immunoenzymatic test. SN003 (0.5\u00a0mg/kg) potentiated the antidepressant-like effect of imipramine (15 mg/kg) and fluoxetine (7.5\u00a0mg/kg). Moreover, the co-administration of the tested agents abolished CORT-induced increase in CRF levels in the examined biological material more profoundly than monotherapy. Our present findings give further evidence that the blockage of CRF action may be useful in the treatment of mood disorders. The concurrent use of well-known antidepressants with CRF<sub>1</sub> receptor antagonists could be beneficial in terms of safety, since it requires lower doses of the applied agents."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Second Department of Gynecology, Medical University of Lublin, Jaczewskiego 8, 20-090, Lublin, Poland."}], "LastName": "Wr\u00f3bel", "ForeName": "Andrzej", "Initials": "A"}, {"Identifier": ["0000-0002-5732-8950"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chair and Department of Applied Pharmacy, Medical University of Lublin, Chod\u017aki 1, 20-093, Lublin, Poland. anna.serefko@umlub.pl."}], "LastName": "Serefko", "ForeName": "Anna", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chair and Department of Applied Pharmacy, Medical University of Lublin, Chod\u017aki 1, 20-093, Lublin, Poland."}], "LastName": "Szopa", "ForeName": "Aleksandra", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chair and Department of Applied Pharmacy, Medical University of Lublin, Chod\u017aki 1, 20-093, Lublin, Poland."}], "LastName": "Rojek", "ForeName": "Karol", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chair and Department of Applied Pharmacy, Medical University of Lublin, Chod\u017aki 1, 20-093, Lublin, Poland."}], "LastName": "Poleszak", "ForeName": "Ewa", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy with Medicinal Plants Unit, Medical University of Lublin, Chod\u017aki 1, 20-093, Lublin, Poland."}], "LastName": "Skalicka-Wo\u017aniak", "ForeName": "Krystyna", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology, Medical University of Lublin, Jaczewskiego 8B, 20-093, Lublin, Poland."}], "LastName": "Dudka", "ForeName": "Jaros\u0142aw", "Initials": "J"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Germany", "MedlineTA": "Naunyn Schmiedebergs Arch Pharmacol", "NlmUniqueID": "0326264", "ISSNLinking": "0028-1298"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antidepressive Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyridines"}, {"RegistryNumber": "0", "NameOfSubstance": "Receptors, Corticotropin-Releasing Hormone"}, {"RegistryNumber": "0", "NameOfSubstance": "SN003"}, {"RegistryNumber": "0", "NameOfSubstance": "Triazoles"}, {"RegistryNumber": "01K63SUP8D", "NameOfSubstance": "Fluoxetine"}, {"RegistryNumber": "5CLY6W2H1M", "NameOfSubstance": "CRF receptor type 1"}, {"RegistryNumber": "9015-71-8", "NameOfSubstance": "Corticotropin-Releasing Hormone"}, {"RegistryNumber": "OGG85SX4E4", "NameOfSubstance": "Imipramine"}, {"RegistryNumber": "W980KJ009P", "NameOfSubstance": "Corticosterone"}], "MeshHeadingList": [{"QualifierName": ["drug effects", "metabolism"], "DescriptorName": "Amygdala"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Antidepressive Agents"}, {"QualifierName": ["drug effects"], "DescriptorName": "Behavior, Animal"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Corticosterone"}, {"QualifierName": ["blood", "metabolism"], "DescriptorName": "Corticotropin-Releasing Hormone"}, {"QualifierName": ["drug therapy", "metabolism"], "DescriptorName": "Depression"}, {"QualifierName": [], "DescriptorName": "Drug Therapy, Combination"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Fluoxetine"}, {"QualifierName": ["drug effects", "metabolism"], "DescriptorName": "Hypothalamus"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Imipramine"}, {"QualifierName": ["drug effects"], "DescriptorName": "Locomotion"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Pyridines"}, {"QualifierName": [], "DescriptorName": "Rats, Wistar"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "Receptors, Corticotropin-Releasing Hormone"}, {"QualifierName": [], "DescriptorName": "Swimming"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Triazoles"}], "CoiStatement": "All procedures were performed in accordance with the binding European and Polish law related to experimental studies on animal models, and they were approved by the local ethics committee. FUNDING: This study was supported by the Funds for Statutory Activity of the Medical University of Lublin, Poland. ETHICAL APPROVAL: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. CONFLICT OF INTEREST: The authors declare that they have no conflicts of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol. 1999;160:1\u201312. doi: 10.1677/joe.0.1600001.", "ArticleIdList": ["10.1677/joe.0.1600001", "9854171"]}, {"Citation": "Bourke CH, Glasper ER, Neigh GN. SSRI or CRF antagonism partially ameliorate depressive-like behavior after adolescent social defeat. Behav Brain Res. 2014;270:295\u2013299. doi: 10.1016/j.bbr.2014.05.035.", "ArticleIdList": ["10.1016/j.bbr.2014.05.035", "24867331"]}, {"Citation": "Chaki S, Nakazato A, Kennis L, Nakamura M, Mackie C, Sugiura M, Vinken P, Ashton D, Langlois X, Steckler T. Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450. Eur J Pharmacol. 2004;485:145\u2013158. doi: 10.1016/j.ejphar.2003.11.032.", "ArticleIdList": ["10.1016/j.ejphar.2003.11.032", "14757135"]}, {"Citation": "Chappell PB, Smith MA, Kilts CD, Bissette G, Ritchie J, Anderson C, Nemeroff CB. Alterations in corticotropin-releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress. J Neurosci. 1986;6:2908\u20132914.", "ArticleIdList": ["PMC6568795", "3020187"]}, {"Citation": "De Bellis MD, Gold PW, Geracioti TD, Jr, Listwak SJ, Kling MA. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry. 1993;150:656\u2013657. doi: 10.1176/ajp.150.4.656.", "ArticleIdList": ["10.1176/ajp.150.4.656", "8465888"]}, {"Citation": "Fadda P, Pani L, Porcella A, Fratta W. Chronic imipramine, L-sulpiride and mianserin decrease corticotropin releasing factor levels in the rat brain. Neurosci Lett. 1995;192:121\u2013123. doi: 10.1016/0304-3940(95)11612-Z.", "ArticleIdList": ["10.1016/0304-3940(95)11612-Z", "7675318"]}, {"Citation": "Galard R, Catalan R, Castellanos JM, Gallart JM. Plasma corticotropin-releasing factor in depressed patients before and after the dexamethasone suppression test. Biol Psychiatry. 2002;51:463\u2013468. doi: 10.1016/S0006-3223(01)01273-2.", "ArticleIdList": ["10.1016/S0006-3223(01)01273-2", "11922880"]}, {"Citation": "Gilligan PJ, Robertson DW, Zaczek R. Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. J Med Chem. 2000;43:1641\u20131660. doi: 10.1021/jm990590f.", "ArticleIdList": ["10.1021/jm990590f", "10794681"]}, {"Citation": "Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P, Geslin M, Scatton B, Maffrand JP, Soubrie P. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylp henyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther. 2002;301:333\u2013345. doi: 10.1124/jpet.301.1.333.", "ArticleIdList": ["10.1124/jpet.301.1.333", "11907191"]}, {"Citation": "Heinrichs SC, Koob GF. Corticotropin-releasing factor in brain: a role in activation, arousal, and affect regulation. J Pharmacol Exp Ther. 2004;311:427\u2013440. doi: 10.1124/jpet.103.052092.", "ArticleIdList": ["10.1124/jpet.103.052092", "15297468"]}, {"Citation": "Heuser I, Bissette G, Dettling M, Schweiger U, Gotthardt U, Schmider J, Lammers CH, Nemeroff CB, Holsboer F. Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment. Depress Anxiety. 1998;8:71\u201379. doi: 10.1002/(SICI)1520-6394(1998)8:2<71::AID-DA5>3.0.CO;2-N.", "ArticleIdList": ["10.1002/(SICI)1520-6394(1998)8:2<71::AID-DA5>3.0.CO;2-N", "9784981"]}, {"Citation": "Holsboer F, Ising M. Central CRH system in depression and anxiety\u2014evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol. 2008;583:350\u2013357. doi: 10.1016/j.ejphar.2007.12.032.", "ArticleIdList": ["10.1016/j.ejphar.2007.12.032", "18272149"]}, {"Citation": "Joanny P, Steinberg J, Zamora AJ, Conte-Devolx B, Millet Y, Oliver C. Corticotropin-releasing factor release from in vitro superfused and incubated rat hypothalamus. Effect of potassium, norepinephrine, and dopamine. Peptides. 1989;10:903\u2013911. doi: 10.1016/0196-9781(89)90167-8.", "ArticleIdList": ["10.1016/0196-9781(89)90167-8", "2514417"]}, {"Citation": "Lee B, Shim I, Lee HJ, Yang Y, Hahm DH. Effects of acupuncture on chronic corticosterone-induced depression-like behavior and expression of neuropeptide Y in the rats. Neurosci Lett. 2009;453:15\u201316.", "ArticleIdList": ["19429024"]}, {"Citation": "Mansbach RS, Brooks EN, Chen YL. Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist. Eur J Pharmacol. 1997;323:21\u201326. doi: 10.1016/S0014-2999(97)00025-3.", "ArticleIdList": ["10.1016/S0014-2999(97)00025-3", "9105872"]}, {"Citation": "Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry. 1988;45:577\u2013579. doi: 10.1001/archpsyc.1988.01800300075009.", "ArticleIdList": ["10.1001/archpsyc.1988.01800300075009", "2837159"]}, {"Citation": "Overstreet DH, Keeney A, Hogg S. Antidepressant effects of citalopram and CRF receptor antagonist CP-154,526 in a rat model of depression. Eur J Pharmacol. 2004;492:195\u2013201. doi: 10.1016/j.ejphar.2004.04.010.", "ArticleIdList": ["10.1016/j.ejphar.2004.04.010", "15178365"]}, {"Citation": "Paxinos, G., Watson, C (2008) The Rat Brain in Stereotaxic Coordinates. Compact Sixth Edition, Elsevier"}, {"Citation": "Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther. 1977;229:327\u2013336.", "ArticleIdList": ["596982"]}, {"Citation": "Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327\u2013336.", "ArticleIdList": ["12811491"]}, {"Citation": "Takahashi LK, Ho SP, Livanov V, Graciani N, Arneric SP. Antagonism of CRF(2) receptors produces anxiolytic behavior in animal models of anxiety. Brain Res. 2001;902:135\u2013142. doi: 10.1016/S0006-8993(01)02405-2.", "ArticleIdList": ["10.1016/S0006-8993(01)02405-2", "11384606"]}, {"Citation": "Veith RC, Lewis N, Langohr JI, Murburg MM, Ashleigh EA, Castillo S, Peskind ER, Pascualy M, Bissette G, Nemeroff CB. Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. Psychiatry Res. 1993;46:1\u20138. doi: 10.1016/0165-1781(93)90002-X.", "ArticleIdList": ["10.1016/0165-1781(93)90002-X", "8464952"]}, {"Citation": "Wrobel A, Serefko A, Poleszak E, Rechberger T. Fourteen-day administration of corticosterone may induce detrusor overactivity symptoms. Int Urogynecol J. 2016;27:1713\u20131721. doi: 10.1007/s00192-016-3027-3.", "ArticleIdList": ["10.1007/s00192-016-3027-3", "PMC5065892", "27142032"]}, {"Citation": "Yamano M, Yuki H, Yasuda S, Miyata K. Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice. J Pharmacol Exp Ther. 2000;292:181\u2013187.", "ArticleIdList": ["10604946"]}, {"Citation": "Zhang G, Huang N, Li YW, Qi X, Marshall AP, Yan XX, Hill G, Rominger C, Prakash SR, Bakthavatchalam R, Rominger DH, Gilligan PJ, Zaczek R. Pharmacological characterization of a novel nonpeptide antagonist radioligand, (+/\u2212)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for corticotropin-releasing factor1 receptors. J Pharmacol Exp Ther. 2003;305:57\u201369. doi: 10.1124/jpet.102.046128.", "ArticleIdList": ["10.1124/jpet.102.046128", "12649353"]}, {"Citation": "Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res. 2000;34:171\u2013181. doi: 10.1016/S0022-3956(00)00016-9.", "ArticleIdList": ["10.1016/S0022-3956(00)00016-9", "10867111"]}]}], "History": [{"Year": "2017", "Month": "1", "Day": "19"}, {"Year": "2017", "Month": "4", "Day": "10"}, {"Year": "2017", "Month": "4", "Day": "22", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "5", "Day": "10", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "4", "Day": "22", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "4", "Day": "20"}], "PublicationStatus": "ppublish", "ArticleIdList": ["28429110", "PMC5509780", "10.1007/s00210-017-1377-0", "10.1007/s00210-017-1377-0"]}}]}